Literature DB >> 30638433

Mortality in US veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors.

Aaron W Trammell1,2, Amit J Shah2,3, Lawrence S Phillips2,4, C Michael Hart1,2.   

Abstract

Pulmonary hypertension (PH) occurs when the pulmonary vasculature is itself diseased or becomes affected secondarily by comorbid conditions, commonly left heart or lung disease. The high prevalence of chronic cardiopulmonary conditions among patients served by Veterans Health Administration (VHA) suggests this population may be particularly susceptible to PH. We sought to identify clinical features and outcomes in veterans diagnosed with PH. We utilized the VHA Corporate Data Warehouse to identify veterans diagnosed between January 1, 2003 and September 30, 2015, assess relevant patient characteristics and their survival time. The effects of PH subtype and baseline factors on outcome were estimated by Cox modeling. There were 110,564 veterans diagnosed with PH during the study period. These veterans were predominantly male, had median age 70.2, and had a high burden of comorbid conditions. PH was frequently due to left heart and/or lung disease. Average survival after PH diagnosis was 3.88 years. Compared with other types, PH due to left heart disease, lung disease or both had shorter survival. This large retrospective study of veterans demonstrates the significance of PH due to left heart and/or lung disease which was common and had high risk of death. Multi-comorbidity was common and added to risk. These findings underscore the need for risk assessment tools for subjects with non-Group 1 PH and novel management strategies to improve their outcome. This study details the largest retrospective cohort assembled for evaluation of secondary PH and allows hypothesis-generating inquiries into these common conditions that are rarely prospectively studied.

Entities:  

Keywords:  comorbidity; pulmonary hypertension; retrospective cohort study; risk factors; survival

Year:  2019        PMID: 30638433      PMCID: PMC6381440          DOI: 10.1177/2045894019825763

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  41 in total

1.  Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients.

Authors:  Carrie N Klabunde; Linda C Harlan; Joan L Warren
Journal:  Med Care       Date:  2006-10       Impact factor: 2.983

2.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension.

Authors:  Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes
Journal:  J Heart Lung Transplant       Date:  2011-04-13       Impact factor: 10.247

3.  Insulin resistance in pulmonary arterial hypertension.

Authors:  R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

4.  ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre.

Authors:  J Hurdman; R Condliffe; C A Elliot; C Davies; C Hill; J M Wild; D Capener; P Sephton; N Hamilton; I J Armstrong; C Billings; A Lawrie; I Sabroe; M Akil; L O'Toole; D G Kiely
Journal:  Eur Respir J       Date:  2011-09-01       Impact factor: 16.671

5.  Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline.

Authors:  Sanjay Mehta; Doug Helmersen; Steeve Provencher; Naushad Hirani; Fraser D Rubens; Marc De Perrot; Mark Blostein; Kim Boutet; George Chandy; Carole Dennie; John Granton; Paul Hernandez; Andrew M Hirsch; Karen Laframboise; Robert D Levy; Dale Lien; Simon Martel; Gerard Shoemaker; John Swiston; Justin Weinkauf
Journal:  Can Respir J       Date:  2010 Nov-Dec       Impact factor: 2.409

6.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

7.  Association of the metabolic syndrome with pulmonary venous hypertension.

Authors:  Ivan M Robbins; John H Newman; Roger F Johnson; Anna R Hemnes; Richard D Fremont; Robert N Piana; David X Zhao; Daniel W Byrne
Journal:  Chest       Date:  2009-02-02       Impact factor: 9.410

8.  Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort.

Authors:  Geoff Strange; David Playford; Simon Stewart; Jenny A Deague; Helen Nelson; Aaron Kent; Eli Gabbay
Journal:  Heart       Date:  2012-07-03       Impact factor: 5.994

9.  Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?

Authors:  David E Green; Roy L Sutliff; C Michael Hart
Journal:  Pulm Circ       Date:  2011-01-01       Impact factor: 3.017

10.  Accuracy and completeness of mortality data in the Department of Veterans Affairs.

Authors:  Min-Woong Sohn; Noreen Arnold; Charles Maynard; Denise M Hynes
Journal:  Popul Health Metr       Date:  2006-04-10
View more
  5 in total

1.  Pulmonary Hypertension: A New Vascular Complication of Diabetes?

Authors:  Julia W Gallini; David Benkeser; Xiangqin Cui; Amit J Shah; Lawrence S Phillips; Anna R Hemnes; C Michael Hart; Aaron W Trammell
Journal:  Chest       Date:  2021-09-17       Impact factor: 10.262

Review 2.  The Role of Regulatory T Cells in Pulmonary Arterial Hypertension.

Authors:  Wen Tian; Shirley Y Jiang; Xinguo Jiang; Rasa Tamosiuniene; Dongeon Kim; Torrey Guan; Siham Arsalane; Shravani Pasupneti; Norbert F Voelkel; Qizhi Tang; Mark R Nicolls
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 8.786

3.  Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015.

Authors:  Kari R Gillmeyer; Seppo T Rinne; Mark E Glickman; Kyung Min Lee; Qing Shao; Shirley X Qian; Elizabeth S Klings; Bradley A Maron; Joseph T Hanlon; Donald R Miller; Renda Soylemez Wiener
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-05-12

Review 4.  Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database.

Authors:  Gustavo A Heresi; Bonnie B Dean; Howard Castillo; Henry F Lee; Peter Classi; Dana Stafkey-Mailey; Alexander Kantorovich; Kellie Morland; Margaret R Sketch; Benjamin S Wu; Christopher S King
Journal:  Lung       Date:  2022-03-29       Impact factor: 2.584

5.  Hospital outcomes for patients with pulmonary arterial hypertension in sepsis and septic shock.

Authors:  Rhythm Vasudeva; Abhiram Challa; Nicholas Tuck; Suveeenkrishna Pothuru; Mohinder Vindhyal
Journal:  BMC Pulm Med       Date:  2022-10-03       Impact factor: 3.320

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.